RxDoctor Payments Data

Gurbinder Brar, MD

Internal Medicine · Fresno, CANPI 1861569022

Payments from drug & device makers

$589in general payments, 2019–2025

Across 26 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$160
  • AbbVie$79
  • Pfizer$41
  • GSK$40
  • Exact Sciences$38
  • Lilly USA, LLC$32
  • plus $199 from 9 others

What the payments were for

  • Food & beverage$589100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$589 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$180,870
Medicare patients
269
Services billed
2,480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide25$30,641
EliquisApixaban22$19,154
JardianceEmpagliflozin11$18,484
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$11,842
OzempicSemaglutide11$9,997
Arnuity ElliptaFluticasone Furoate11$3,234
SynthroidLevothyroxine Sodium25$2,793
Levothyroxine Sodium234$2,596
Ezetimibe109$2,555
Metoprolol Succinate150$2,401
Estradiol30$2,378
Rosuvastatin Calcium134$2,051
Atorvastatin Calcium198$1,778
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen53$1,423
Telmisartan33$1,401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$32$30,64125 claims
PfizerEliquis$41$19,15422 claims
GSKTrelegy Ellipta, Arnuity Ellipta$40$15,07626 claims
Novo NordiskOzempic$21$9,99711 claims
AbbVieSynthroid$79$2,79325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →